Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
521-540 of 2,251 trials

HIV Treatment: Doravirine/Tenofovir/Lamivudine Study

We are studying a combination of medications for people living with HIV who have a history of specific mutations. The goal is to see if this treatment helps maintain viral control and improves health over time.

HIV Disease1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Acute Myeloid Leukemia: DASATINIB Treatment Study

We are evaluating the effectiveness of DASATINIB for patients with acute myeloid leukemia who did not respond to previous treatments. The study aims to see if this medication can help reduce tumors and identify factors that predict response.

Acute Myeloid Leukemia≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Surgery: Buckberg vs. Del Nido Cardioplegia

We are comparing two heart protection solutions used during surgery to see which one better safeguards the heart and leads to fewer complications. This study is for patients undergoing isolated myocardial revascularization surgery.

Cardiovascular DiseaseMonitoring phase (IV)No PlaceboStandard Medicines

Lung Cancer: Enhanced Skin Care Management

We are studying if improved skin care can help reduce skin side effects in patients with advanced EGFR-mutated lung cancer receiving amivantamab and lazertinib. This trial compares enhanced care to standard skin management.

EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteDermatologyOncology

Breast Cancer Treatment: OP-1250 vs Standard Care

We are studying a new medication, OP-1250, for people with advanced or metastatic ER+, HER2- breast cancer. The goal is to see if it is safer and more effective than current standard treatments.

Estrogen Receptor Positive Breast CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Stem Cell Transplantation vs. Immunosuppressive Therapy for Systemic Sclerosis

We are studying whether upfront stem cell transplantation is more effective than immunosuppressive medication for early diffuse cutaneous systemic sclerosis. This trial will help us understand the best treatment approach for improving survival and quality of life.

Diffuse Cutaneous Systemic SclerosisMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Peptide Receptor Radionuclide Therapy: LA-SSA Study

We are investigating how a long-acting medication affects radiation doses in tumors and normal tissues during treatment for certain cancers. This may help improve the effectiveness and safety of future therapies.

Neuroendocrine Tumors (NETs)3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Metastatic Castration-Resistant Prostate Cancer: Gedatolisib and Darolutamide Study

We are studying a new combination of gedatolisib and darolutamide for men with metastatic castration-resistant prostate cancer. The trial will evaluate safety, tolerability, and how well this treatment works.

Castration-Resistant Prostate Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Acute Myeloid Leukemia: Personalized Treatment Based on FLT3 Mutation

We are studying a new treatment strategy for patients with FLT3-positive AML, using a biomarker to tailor therapy. The goal is to see if this approach improves survival compared to standard treatments.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Acute Myeloid Leukemia: RVU120 with Venetoclax

We are studying a new treatment combining RVU120 and Venetoclax for patients with acute myeloid leukemia who did not respond to earlier therapies. The goal is to assess its safety and effectiveness in improving their condition.

Acute Myeloid Leukemia6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Sinonasal Carcinoma: Pembrolizumab and Chemotherapy

We are studying the safety and effectiveness of combining pembrolizumab with chemotherapy for patients with locally advanced sinonasal carcinoma. This trial aims to explore new treatment options for better outcomes.

Locally Advanced Sinonasal Carcinoma1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyOtolaryngology

IgM Monoclonal Gammopathy: Zanubrutinib and Rituximab Study

We are investigating whether a new treatment combining Zanubrutinib with Rituximab can improve nerve function in patients with IgM monoclonal gammopathy and related nerve damage. The study will also look at safety and how well patients tolerate the treatment.

Anti-MAG Neuropathy>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Obesity Surgery: Opioid Sparing Care Pathway

We are studying a new pain management approach for patients undergoing obesity surgery to see if it helps reduce opioid use and improve recovery. This may lead to better health outcomes and less reliance on pain medications.

Postoperative PainObesity>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Ovarian Cancer: 68Ga-FAPI PET/CT Imaging Study

We are comparing a new imaging technique to standard methods for diagnosing and monitoring ovarian cancer. This study aims to see if the new method improves patient management and safety.

Ovarian Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyOtolaryngology

Osteoporosis Treatment: The OPTIMIST Study on Romosozumab

We are exploring the best ways to use romosozumab for osteoporosis treatment. Additionally, we’re investigating if it has any impact on insulin sensitivity.

Osteoporosis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Postoperative Recovery: Spinal Morphine vs. Intravenous Lidocaine

We are studying if adding spinal morphine to pain management helps patients recover better after robotic-assisted upper urinary tract surgery. The goal is to see if it reduces pain and speeds up recovery compared to standard treatment.

Kidney and Ureter Disorders6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineNephrologyOncologyOtolaryngologyUrology

TAK-881 for Primary Immunodeficiency Diseases

We are studying the long-term safety and tolerability of TAK-881 in individuals with Primary Immunodeficiency Diseases. This trial will also assess how well the treatment works and its effects on patients' quality of life.

Primary Immunodeficiency Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInfectious Diseases

Persistent Atrial Fibrillation: Cryoballoon vs. Medication

We are studying whether early treatment with a cryoballoon is more effective than antiarrhythmic drugs for people with persistent atrial fibrillation. The trial also looks at how these treatments affect quality of life and healthcare needs.

Persistent Symptomatic Atrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Basal Cell Carcinoma: Tirbanibulin (Klisyri®) Treatment Study

We are studying the effectiveness and safety of Tirbanibulin (Klisyri®) for treating superficial basal cell carcinoma. The trial will also look at how well patients tolerate the treatment and their overall satisfaction.

Superficial Basal Cell Carcinoma≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatology

Anal Cancer Treatment: Induction Chemotherapy Study

We are studying a new treatment approach for locally advanced anal squamous cell carcinoma to see if adding induction chemotherapy improves outcomes compared to standard treatment. This trial will help us understand its effects on survival and quality of life.

Locally Advanced Anal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology